BIOD-123: Completed Phase II enrollment

Biodel completed enrollment of about 130 Type I diabetics in an open-label, U.S. Phase II trial comparing BIOD-123 plus Lantus insulin glargine vs. Humalog insulin lispro plus Lantus for 18 weeks. ...